Elisa Gremese

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3471866/publications.pdf

Version: 2024-02-01

215 papers	6,354 citations	76196 40 h-index	95083 68 g-index
222 all docs	222 docs citations	222 times ranked	8796 citing authors

#	Article	IF	Citations
1	Correspondence on â€˜Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysisâ€™. Annals of the Rheumatic Diseases, 2023, 82, e5-e5.	0.5	6
2	Correspondence on â€˜Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registryâ€™ by Gianfrancesco Met al. The impact of cardiovascular comorbidity on COVID-19 infection in a large cohort of rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2023, 82, e159-e159.	0.5	1
3	Correspondence on â€œAssociations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registryâ€•by Sparkset al. Annals of the Rheumatic Diseases, 2023, 82, e157-e157.	0.5	2
4	Correspondence to â€˜Gender gap in rheumatology: speaker representation at annual conferencesâ€™ by Monga and Liewâ€"gender discrepancies at annual EULAR congresses: towards the gap narrowing. Annals of the Rheumatic Diseases, 2022, 81, e169-e169.	0.5	6
5	Immune-Guided Therapy of COVID-19. Cancer Immunology Research, 2022, 10, 384-402.	1.6	20
6	Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. Annals of the Rheumatic Diseases, 2022, 81, 823-830.	0.5	18
7	Pro Nerve Growth Factor and Its Receptor p75NTR Activate Inflammatory Responses in Synovial Fibroblasts: A Novel Targetable Mechanism in Arthritis. Frontiers in Immunology, 2022, 13, 818630.	2.2	6
8	European bio-naÃ¯ve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response. Rheumatology, 2022, 61, 3799-3807.	0.9	7
9	Infectious agents breaking the immunological tolerance: The holy grail in rheumatoid arthritis reconsidered. Autoimmunity Reviews, 2022, 21, 103102.	2.5	3
10	MO038: Mineral bone density assessment in patients affected by cystinuria. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
11	C-reactive protein and 10-year cardiovascular risk in rheumatoid arthritis. European Journal of Internal Medicine, 2022, 104, 49-54.	1.0	14
12	Comprehensive review on intravertebral intraspinal, intrajoint, and intradiscal vacuum phenomenon: From anatomy and physiology to pathology. Modern Rheumatology, 2021, 31, 303-311.	0.9	11
13	Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?. Annals of the Rheumatic Diseases, 2021, 80, e29-e29.	0.5	6
14	Telemedicine will not keep us apart in COVID-19 pandemic. Annals of the Rheumatic Diseases, 2021, 80, e48-e48.	0.5	21
15	Comparative analysis of synovial inflammation after SARS-CoV-2 infection. Annals of the Rheumatic Diseases, 2021, 80, e91-e91.	0.5	40
16	Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients. Rheumatology, 2021, 60, 728-736.	0.9	15
17	Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. Joint Bone Spine, 2021, 88, 105062.	0.8	14
18	Psoriatic arthritis and depressive symptoms: does systemic inflammation play a role?. Clinical Rheumatology, 2021, 40, 1893-1902.	1.0	5

#	Article	IF	Citations
19	Predictive Factors for a New Positive Nasopharyngeal Swab Among Patients Recovered From COVID-19. American Journal of Preventive Medicine, 2021, 60, 13-19.	1.6	34
20	Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. Microvascular Research, 2021, 133, 104071.	1.1	49
21	Predicting <scp>Inâ€Hospital</scp> Mortality in <scp>COVID</scp>â€19 Older Patients with Specifically Developed Scores. Journal of the American Geriatrics Society, 2021, 69, 37-43.	1.3	62
22	Basophil activation and serum ILâ€5 levels as possible monitor biomarkers in severe eosinophilic asthma patients treated with antiâ€ILâ€5 drugs. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1569-1571.	2.7	6
23	Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients. Expert Opinion on Biological Therapy, 2021, 21, 97-104.	1.4	3
24	The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients. Rheumatology Advances in Practice, 2021, 5, rkab015.	0.3	5
25	The pathogenesis of microthrombi in COVIDâ€19 cannot be controlled by DOAC: NETosis should be the target. Journal of Internal Medicine, 2021, 289, 420-421.	2.7	17
26	Systemic Bone Density at Disease Onset Is Associated With Joint Erosion Progression in Early Naive to Treatment Rheumatoid Arthritis: A Prospective 12-Month Follow-Up Open-Label Study. Frontiers in Medicine, 2021, 8, 613889.	1.2	8
27	Loss of Î±2-6 sialylation promotes the transformation of synovial fibroblasts into a pro-inflammatory phenotype in arthritis. Nature Communications, 2021, 12, 2343.	5.8	28
28	Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry. Clinical Rheumatology, 2021, 40, 4039-4047.	1.0	3
29	Simultaneous Onset of Mycobacterium kansasii Pulmonary Infection and Systemic Lupus Erythematosus: A Case Report. American Journal of Case Reports, 2021, 22, e929866.	0.3	0
30	RAASI, NSAIDs, antidiabetics, and anticoagulants: More data needed to be labeled as harmful or neutral in SARS-CoV-2 infection. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2025609118.	3.3	1
31	Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. Annals of the Rheumatic Diseases, 2021, 80, 1419-1428.	0.5	17
32	COVID-19 and RA share an SPP1 myeloid pathway that drives PD-L1+ neutrophils and CD14+ monocytes. JCI Insight, 2021, 6, .	2.3	35
33	Inclusion of Synovial Tissueâ€"Derived Characteristics in a Nomogram for the Prediction of Treatment Response in Treatmentâ€Naive Rheumatoid Arthritis Patients. Arthritis and Rheumatology, 2021, 73, 1601-1613.	2.9	22
34	Haemophilus parasuis (Glaesserella parasuis) as a Potential Driver of Molecular Mimicry and Inflammation in Rheumatoid Arthritis. Frontiers in Medicine, 2021, 8, 671018.	1.2	15
35	Compassionate use of anti-IL6 receptor antibodies in critically ill patients with acute respiratory distress syndrome due to SARS-COV-2. Minerva Anestesiologica, 2021, 87, 1080-1090.	0.6	3
36	Depression and Endothelial Dysfunction in Psoriatic Arthritis: Is There Any Possible Relationship?. Frontiers in Medicine, 2021, 8, 669397.	1.2	0

#	Article	IF	Citations
37	Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey. International Journal of Clinical Practice, 2021, 75, e14755.	0.8	13
38	Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort. Journal of Autoimmunity, 2021, 124, 102729.	3.0	23
39	Patterns of Anti-Inflammatory and Immunomodulating Drug Usage and Microvascular Endothelial Function in Rheumatoid Arthritis. Frontiers in Cardiovascular Medicine, 2021, 8, 681327.	1.1	1
40	Reply to: Individuality of the composition of the human microbiota by FernÃ¡ndez-EstupiÃ±Ã¡n et al. Clinical and Experimental Rheumatology, 2021, 39 Suppl 128, 34.	0.4	0
41	An unusual lung involvement in scleroderma: lipoid pneumonia. Clinical and Experimental Rheumatology, 2021, 39 Suppl 131, 161-162.	0.4	0
42	High CD14+ peripheral monocytes expression of ALX/FPR2 and BLT1 in low disease activity and remission status in rheumatoid arthritis: a piltot study. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
43	An unusual lung involvement in scleroderma: lipoid pneumonia. Clinical and Experimental Rheumatology, 2021, 39, 161-162.	0.4	1
44	Sex-associated and gender-associated differences in the diagnosis and management of axial spondyloarthritis: addressing the unmet needs of female patients. RMD Open, 2021, 7, e001681.	1.8	28
45	Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity. Annals of Laboratory Medicine, 2020, 40, 101-113.	1.2	14
46	Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. Internal Medicine Journal, 2020, 50, 1085-1090.	0.5	75
47	O14â€ƒSemi-quantitative assessment of synovial inflammation on US guided synovial membrane biopsy is contingent to disease phase, autoimmune profile and treatment response in RA: a large single center experience. Rheumatology, 2020, 59, .	0.9	0
48	P234â€ƒCharacterisation of human synovial tissue dendritic cells in rheumatoid arthritis patients. Rheumatology, 2020, 59, .	0.9	0
49	No higher risk of respiratory symptoms in Italian rheumatological patients under IL-6R-inhibitor therapy in SARS-CoV-2 pandemic. Rheumatology, 2020, 59, 2644-2646.	0.9	0
50	Adult Onset Still's Disease and Radiotherapy treatment for breast cancer: Case report about management of this rare association and literature review. Reports of Practical Oncology and Radiotherapy, 2020, 25, 527-532.	0.3	2
51	What can we learn from rapidly progressive interstitial lung disease related to anti-MDA5 dermatomyositis in the management of COVID-19?. Autoimmunity Reviews, 2020, 19, 102666.	2.5	24
52	Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID-19. Alimentary Pharmacology and Therapeutics, 2020, 52, 902-903.	1.9	9
53	Sarilumab use in severe SARS-CoV-2 pneumonia. EClinicalMedicine, 2020, 27, 100553.	3.2	66
54	Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study. Rheumatology, 2020, 59, 3731-3736.	0.9	21

#	Article	IF	Citations
55	Assessment of neurological manifestations in hospitalized patients with COVIDâ€19. European Journal of Neurology, 2020, 27, 2322-2328.	1.7	36
56	COVID-19 and intestinal inflammation: Role of fecal calprotectin. Digestive and Liver Disease, 2020, 52, 1231-1233.	0.4	40
57	Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies. Frontiers in Medicine, 2020, 7, 553075.	1.2	7
58	Pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatology, The, 2020, 2, e458.	2.2	7
59	HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?. RMD Open, 2020, 6, e001171.	1.8	2
60	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2020, 8, 963-974.	5.2	348
61	Positive RT-PCR nasopharyngeal swab in patients recovered from COVID-19 disease: When does quarantine really end?. Journal of Infection, 2020, 81, e1-e3.	1.7	40
62	Multidisciplinary Evaluation of Interstitial Lung Diseases: New Opportunities Linked to Rheumatologist Involvement. Diagnostics, 2020, 10, 664.	1.3	15
63	Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry. Archives of Rheumatology, 2020, 35, 163-169.	0.3	3
64	Treatment strategy introducing immunosuppressive drugs with glucocorticoids ab initio or very early in giant cell arteritis: A multicenter retrospective controlled study. Journal of Translational Autoimmunity, 2020, 3, 100072.	2.0	5
65	One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. Expert Opinion on Biological Therapy, 2020, 20, 813-821.	1.4	40
66	Post-COVID-19 global health strategies: the need for an interdisciplinary approach. Aging Clinical and Experimental Research, 2020, 32, 1613-1620.	1.4	167
67	Comment on: Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis. Rheumatology, 2020, 59, 1782-1783.	0.9	1
68	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. Frontiers in Medicine, 2020, 7, 42.	1.2	21
69	Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. Nature Medicine, 2020, 26, 1295-1306.	15.2	304
70	Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab. Infection, 2020, 48, 767-771.	2.3	26
71	Basic immunology may lead to translational therapeutic rationale: SARSâ€CoVâ€2 and rheumatic diseases. European Journal of Clinical Investigation, 2020, 50, e13342.	1.7	11
72	Morbidity and Mortality From COVIDâ€19 Are Not Increased Among Children or Patients With Autoimmune Rheumatic Diseaseâ€"Possible Immunologic Rationale: Comment on the Article by Henderson et al. Arthritis and Rheumatology, 2020, 72, 1772-1774.	2.9	3

#	Article	IF	Citations
73	Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors. Journal of Autoimmunity, 2020, 108, 102397.	3.0	26
74	Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations. Clinical Immunology, 2020, 214, 108395.	1.4	16
75	Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Realâ€Life Setting. Arthritis and Rheumatology, 2020, 72, 1314-1324.	2.9	58
76	Ultrasonography involvement of carotid, upper and lower limb arteries in a large cohort of systemic sclerosis patients. International Journal of Rheumatic Diseases, 2020, 23, 681-692.	0.9	3
77	Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis. Rheumatology, 2020, 59, 2523-2533.	0.9	35
78	Demographic and clinical differences between ankylosing spondylitis and non-radiographic axial spondyloarthritis: results from a multicentre retrospective study in the Lazio region of Italy. Clinical and Experimental Rheumatology, 2020, 38, 88-93.	0.4	5
79	Gut microbiota analysis in systemic sclerosis according to disease characteristics and nutritional status. Clinical and Experimental Rheumatology, 2020, 38 Suppl 125, 73-84.	0.4	3
80	Measuring the Tâ€cell downâ€regulation of TCRâ€zeta, ZAPâ€70 and CD28 in arthritis patients: An old tool for new biomarkers. European Journal of Immunology, 2019, 49, 2195-2203.	1.6	3
81	JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy. Journal of Leukocyte Biology, 2019, 106, 1063-1068.	1.5	38
82	Overweight/obesity affects histological features and inflammatory gene signature of synovial membrane of Rheumatoid Arthritis. Scientific Reports, 2019, 9, 10420.	1.6	17
83	Adult onset Still's disease and pregnancy. Autoimmunity Reviews, 2019, 18, 102356.	2.5	7
84	The B side of rheumatoid arthritis pathogenesis. Pharmacological Research, 2019, 149, 104465.	3.1	13
85	PsA-Disk, a novel visual instrument to evaluate psoriatic arthritis in psoriatic patients: an Italian derma-rheuma multicentre study. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231984705.	1.1	4
86	Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis. Arthritis Research and Therapy, 2019, 21, 116.	1.6	23
87	Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study. European Journal of Internal Medicine, 2019, 66, 57-61.	1.0	9
88	Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. Digestive and Liver Disease, 2019, 51, 972-977.	0.4	25
89	Long-Term Retention Rate of Anakinra in Adult Onset Stillâ€™s Disease and Predictive Factors for Treatment Response. Frontiers in Pharmacology, 2019, 10, 296.	1.6	35
90	Comment on: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease. Rheumatology, 2019, 58, 1113-1115.	0.9	9

#	Article	IF	Citations
91	Quantitative and semi-quantitative computed tomography analysis of interstitial lung disease associated with systemic sclerosis: A longitudinal evaluation of pulmonary parenchyma and vessels. PLoS ONE, 2019, 14, e0213444.	1.1	28
92	Selective Inhibitors of T Cell Receptor Recognition of Antigenâ€"MHC Complexes for Rheumatoid Arthritis. ACS Medicinal Chemistry Letters, 2019, 10, 644-649.	1.3	10
93	Amplifying the concept of psoriatic arthritis: The role of autoimmunity in systemic psoriatic disease. Autoimmunity Reviews, 2019, 18, 565-575.	2.5	49
94	Microvascular heart involvement in systemic autoimmune diseases: The purinergic pathway and therapeutic insights from the biology of the diseases. Autoimmunity Reviews, 2019, 18, 317-324.	2.5	7
95	AB0253â€…BIOMARKERS OF CLINICAL RESPONSE TO IL6-R BLOCKADE IN DMARDS INCOMPLETE RESPONDERS (AR-BIOM TRIAL): IL23 AND BAFF AS BIOLOGICAL TARGETS, AND ALBUMIN AS BIOLOGICAL PREDICTOR. , 2019, , .		0
96	SAT0090â€…GUT MICROBIOTA COMPOSITION IS CONTINGENT WITH DISEASE PHASES IN RHEUMATOID ARTHRITIS. , 2019, , .		0
97	Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease. United European Gastroenterology Journal, 2019, 7, 1189-1197.	1.6	31
98	Diagnostic performance of FDG PET in large vessel vasculitis. Clinical and Translational Imaging, 2019, 7, 415-425.	1.1	1
99	Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteenâ€Week ResultsÂFrom a Phase <scp>III</scp> Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. Arthritis and Rheumatology, 2019, 71, 599-611.	2.9	142
100	Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective study. European Journal of Internal Medicine, 2019, 60, 46-53.	1.0	43
101	Anti-MÃ¼llerian hormone serum levels in systemic lupus erythematosus patients: Influence of the disease severity and therapy on the ovarian reserve. Endocrine, 2019, 63, 369-375.	1.1	23
102	Factors predicting early discontinuation of methotrexate as a first-line treatment for rheumatoid arthritis in Italy: Results from the GISEA registry. Indian Journal of Rheumatology, 2019, 14, 271.	0.2	1
103	Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA. Clinical and Experimental Rheumatology, 2019, 37, 649-655.	0.4	10
104	Transitional care of young people with juvenile idiopathic arthritis in Italy: results of a Delphi consensus survey. Clinical and Experimental Rheumatology, 2019, 37, 1084-1091.	0.4	2
105	Free light chains of immunoglobulins in patients with systemic sclerosis: correlations with lung involvement and inflammatory milieu. Journal of Clinical Pathology, 2018, 71, 620-625.	1.0	18
106	Should rheumatoid factor (RF) (and antinuclear antibodies (ANA)) become routinary screening test for morbidities in the general population?. Autoimmunity Reviews, 2018, 17, 636-638.	2.5	5
107	Driving chronicity in rheumatoid arthritis: perpetuating role of myeloid cells. Clinical and Experimental Immunology, 2018, 193, 13-23.	1.1	29
108	Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression. Arthritis Research and Therapy, 2018, 20, 75.	1.6	45

#	Article	IF	Citations
109	Interleukin-6 and IgA-rheumatoid factor are crucial for baseline erosiveness, and anti-citrullinated peptide antibodies for radiographic progression in early rheumatoid arthritis treated according to a treat-to-target strategy. Scandinavian Journal of Rheumatology, 2018, 47, 351-359.	0.6	11
110	The UltraSound-CLinical ARthritis Activity (US-CLARA) index: Properties of a new composite disease activity index for rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2018, 47, 619-629.	1.6	9
111	Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologicsâ€™ register GISEA. Clinical Rheumatology, 2018, 37, 315-321.	1.0	37
112	Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. Joint Bone Spine, 2018, 85, 455-459.	0.8	14
113	Statins and Mortality in Connective Tissue Diseases: Should We Resume the Cardio-rheumatology Spirit in Our Clinics?. Journal of Rheumatology, 2018, 45, 1617-1619.	1.0	1
114	The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference. Rheumatology, 2018, 57, vii11-vii22.	0.9	17
115	Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA. Frontiers in Immunology, 2018, 9, 1936.	2.2	71
116	Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. Rheumatology, 2018, 57, vii42-vii53.	0.9	24
117	The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts. Autoimmunity Reviews, 2018, 17, 1251-1258.	2.5	2
118	Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis. RMD Open, 2018, 4, e000667.	1.8	15
119	Prevalence and Determinants of Peripheral Microvascular Endothelial Dysfunction in Rheumatoid Arthritis Patients: A Multicenter Cross-Sectional Study. Mediators of Inflammation, 2018, 2018, 1-8.	1.4	30
120	Synovial Predictors of Differentiation to Definite Arthritis in Patients With Seronegative Undifferentiated Peripheral Inflammatory Arthritis: microRNA Signature, Histological, and Ultrasound Features. Frontiers in Medicine, 2018, 5, 186.	1.2	24
121	Abatacept in the treatment of psoriatic arthritis: biological and clinical profiles of the responders. Immunotherapy, 2018, 10, 807-821.	1.0	10
122	Chemerin and PEDF Are Metaflammation-Related Biomarkers of Disease Activity and Obesity in Rheumatoid Arthritis. Frontiers in Medicine, 2018, 5, 207.	1.2	23
123	Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study. Journal of Crohn's and Colitis, 2018, 12, 1079-1088.	0.6	50
124	Ultrasound assessment as predictor of disease relapse in children and adults with arthritis in clinical stable remission: new findings but still unmet needs. Annals of the Rheumatic Diseases, 2018, 77, 1391-1393.	0.5	5
125	Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?. Annals of the Rheumatic Diseases, 2017, 76, 1228-1236.	0.5	70
126	Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis. Medicine (United States), 2017, 96, e6656.	0.4	43

#	Article	IF	Citations
127	MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis. Nature Communications, 2017, 8, 15877.	5.8	72
128	Baseline Shoulder Ultrasonography Is Not a Predictive Marker of Response to Glucocorticoids in Patients with Polymyalgia Rheumatica: A 12-month Followup Study. Journal of Rheumatology, 2017, 44, 241-247.	1.0	14
129	B cell activating factor (BAFF) and BAFF receptors: fakes and facts. Clinical and Experimental Immunology, 2017, 190, 291-292.	1.1	19
130	Is ACPA positivity the main driver for rheumatoid arthritis treatment? Pros and cons. Autoimmunity Reviews, 2017, 16, 1096-1102.	2.5	20
131	Clinical heterogeneity of SAPHO syndrome: challenging diagnose and treatment. Clinical Rheumatology, 2017, 36, 2151-2158.	1.0	67
132	An autosomal recessiveDNASE1L3-related autoimmune disease with unusual clinical presentation mimicking systemic lupus erythematosus. Lupus, 2017, 26, 768-772.	0.8	40
133	03.13â€...Synovial tissue of ra patients in remission contains a unique population of regulatory macrophages. , 2017, , .		0
134	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Stillâ€™s Disease: A Multicentre Retrospective Observational Study. Frontiers in Pharmacology, 2017, 8, 369.	1.6	89
135	The Role of High-Mobility Group Box-1 and Its Crosstalk with Microbiome in Rheumatoid Arthritis. Mediators of Inflammation, 2017, 2017, 1-11.	1.4	17
136	MicroRNA-155â€"at the Critical Interface of Innate and Adaptive Immunity in Arthritis. Frontiers in Immunology, 2017, 8, 1932.	2.2	170
137	Using a modified Delphi process to establish clinical consensus for the diagnosis, risk assessment and abatacept treatment in patients with aggressive rheumatoid arthritis. Clinical and Experimental Rheumatology, 2017, 35, 772-776.	0.4	3
138	Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. Clinical and Experimental Rheumatology, 2017, 35, 660-665.	0.4	5
139	Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?. Arthritis Research and Therapy, 2016, 18, 126.	1.6	4
140	Immunosuppressive Therapy (Methotrexate or Cyclophosphamide) in Combination with Corticosteroids in the Treatment of Giant Cell Arteritis: Comparison with Corticosteroids Alone. Journal of the American Geriatrics Society, 2016, 64, 672-374.	1.3	8
141	Weight Loss, The Obesity Paradox in Rheumatoid Arthritis: Is It a Paradox? Comment on the Article by Baker et al. Arthritis and Rheumatology, 2016, 68, 553-553.	2.9	1
142	Is Citrullination Required for the Presence of Restricted Clonotypes Reacting With Type II Collagen? Comment on the Article by Chemin et al. Arthritis and Rheumatology, 2016, 68, 2052-2053.	2.9	3
143	Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Science and Medicine, 2016, 3, e000163.	1.1	51
144	The prognostic significance of the Birmingham Vasculitis Activity Score (BVAS) with systemic vasculitis patients transferred to the intensive care unit (ICU). Medicine (United States), 2016, 95, e5506.	0.4	12

#	Article	IF	Citations
145	Drug survival of adalimumab in patients with rheumatoid arthritis over 10Âyears in the real-world settings: high rate remission together with normal function ability. Clinical Rheumatology, 2016, 35, 2649-2656.	1.0	19
146	MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis. Nature Communications, 2016, 7, 12970.	5.8	97
147	Do we need to apply a T2T strategy even in ACPA-negative early rheumatoid arthritis? YES. RMD Open, 2016, 2, e000263.	1.8	6
148	The role of high-mobility group box protein 1 in collagen antibody-induced arthritis is dependent on vascular endothelial growth factor. Clinical and Experimental Immunology, 2016, 184, 62-72.	1.1	17
149	Tapering and discontinuation of TNF-Î± blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission. Arthritis Research and Therapy, 2016, 18, 39.	1.6	62
150	Biomolecular features of inflammation in obese rheumatoid arthritis patients: management considerations. Expert Review of Clinical Immunology, 2016, 12, 751-762.	1.3	18
151	Comment on â€œTumor necrosis factor-Î± antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series studyâ€• Clinical Rheumatology, 2016, 35, 839-840.	1.0	1
152	CTLA-4 Ig as an effective treatment in a patient with type I diabetes mellitus and seropositive rheumatoid arthritis. Clinical and Experimental Rheumatology, 2016, 34, 315-7.	0.4	4
153	Collagen Specific T-Cell Repertoire and HLA-DR Alleles: Biomarkers of Active Refractory Rheumatoid Arthritis. EBioMedicine, 2015, 2, 2037-2045.	2.7	36
154	The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. Rheumatology, 2015, 54, 1074-1079.	0.9	22
155	Detection of bone erosions in early rheumatoid arthritis: 3D ultrasonography versus computed tomography. Clinical Rheumatology, 2015, 34, 1181-1186.	1.0	15
156	Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology, 2015, 54, 891-898.	0.9	129
157	Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement. Journal of rheumatology Supplement, The, 2015, 93, 65-69.	2.2	8
158	Position paper of Italian rheumatologists on the use of biosimilar drugs. Clinical and Experimental Rheumatology, 2015, 33, 1-4.	0.4	22
159	Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. Clinical and Experimental Rheumatology, 2015, 33, 449-56.	0.4	55
160	Memory B cell subsets and plasmablasts are lower in early than in long-standing Rheumatoid Arthritis. BMC Immunology, 2014, 15, 28.	0.9	20
161	Obesity as a Risk and Severity Factor in Rheumatic Diseases (Autoimmune Chronic Inflammatory) Tj ETQq1 1 0.784314 rgBT /Overloc	2.2	110
162	High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register. Clinical Rheumatology, 2014, 33, 31-37.	1.0	10

#	Article	IF	Citations
163	Body weight, gender and response to TNF-Â blockers in axial spondyloarthritis. Rheumatology, 2014, 53, 875-881.	0.9	104
164	Safety of Etanercept and Methotrexate in Patients with Rheumatoid Arthritis and Hepatitis C Virus Infection: A Multicenter Randomized Clinical Trial. Journal of Rheumatology, 2014, 41, 286-292.	1.0	47
165	Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register. Joint Bone Spine, 2014, 81, 508-512.	0.8	21
166	Drug survival on TNF inhibitors: 2003â€"2004 data from Italian National Register (GISEA Register). Annals of the Rheumatic Diseases, 2014, 73, e31-e31.	0.5	8
167	Validation of the classification criteria for cryoglobulinaemic vasculitis. Rheumatology, 2014, 53, 2209-2213.	0.9	67
168	The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program. Clinical and Experimental Rheumatology, 2014, 32, 869-77.	0.4	42
169	Porphyromonas gingivalis and the pathogenesis of rheumatoid arthritis: analysis of various compartments including the synovial tissue. Arthritis Research and Therapy, 2013, 15, R66.	1.6	55
170	Obesity and reduction of the response rate to antiâ€"tumor necrosis factor Î± in rheumatoid arthritis: An approach to a personalized medicine. Arthritis Care and Research, 2013, 65, 94-100.	1.5	170
171	Tofacitinib for rheumatoid arthritis. Lancet, The, 2013, 381, 1812.	6.3	4
172	Temporal ultrasonography findings in temporal arteritis: early disappearance of halo sign after only 2 days of steroid treatment. Rheumatology, 2013, 52, 622-622.	0.9	26
173	Biomarkers of Joint Damage in Rheumatoid Arthritis: Where Are We in 2013?. Journal of Rheumatology, 2013, 40, 1244-1246.	1.0	8
174	Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. Annals of the Rheumatic Diseases, 2013, 72, 858-862.	0.5	112
175	Polymorphisms of the IgH enhancer HS1.2 and risk of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2012, 71, 1309-1315.	0.5	23
176	ZAP-70+ B Cell Subset Influences Response to B Cell Depletion Therapy and Early Repopulation in Rheumatoid Arthritis. Journal of Rheumatology, 2012, 39, 2276-2285.	1.0	5
177	Longterm Retention of Tumor Necrosis Factor-Î± Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors. Journal of Rheumatology, 2012, 39, 1179-1184.	1.0	87
178	Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology, 2012, 51, 157-168.	0.9	89
179	Should We Consider Tumor Necrosis Factor as the Only Target in Spondyloarthritides?. Journal of rheumatology Supplement, The, 2012, 89, 94-96.	2.2	2
180	Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmunity Reviews, 2012, 12, 225-229.	2.5	146

#	Article	IF	Citations
181	Biomarkers of Good EULAR Response to the B Cell Depletion Therapy in All Seropositive Rheumatoid Arthritis Patients: Clues for the Pathogenesis. PLoS ONE, 2012, 7, e40362.	1.1	34
182	Association between the response to B cell depletion therapy and the allele*2 of the HS1,2A enhancer in seropositive rheumatoid arthritis patients. Reumatismo, 2012, 64, 368-73.	0.4	5
183	Rheumatologic Symptoms in Patients with Mixed Cryoglobulinemia. , 2012, , 185-190.		0
184	Rheumatoid arthritis and Alzheimer's disease: genetic and epigenetic links in inflammatory regulation. Discovery Medicine, 2012, 14, 379-88.	0.5	20
185	Clinical and ultrasonographic remission determines different chances of relapse in early and long standing rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 172-175.	0.5	172
186	PTPN22 1858C>T Polymorphism Distribution in Europe and Association with Rheumatoid Arthritis: Case-Control Study and Meta-Analysis. PLoS ONE, 2011, 6, e24292.	1.1	43
187	B-Cell Subsets in the Joint Compartments of Seropositive and Seronegative Rheumatoid Arthritis (RA) and No-RA Arthritides Express Memory Markers and ZAP70 and Characterize the Aggregate Pattern Irrespectively of the Autoantibody Status. Molecular Medicine, 2011, 17, 901-909.	1.9	27
188	Proton pump inhibitors in rheumatic diseases: clinical practice, drug interactions, bone fractures and risk of infections. Reumatismo, 2011, 63, 5-10.	0.4	9
189	The metabolic syndrome: The crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmunity Reviews, 2011, 10, 582-589.	2.5	90
190	Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis. Clinical Immunology, 2011, 138, 107-116.	1.4	55
191	Pathogenetic, clinical and pharmaco-economic assessment in rheumatoid arthritis (RA). Internal and Emergency Medicine, 2011, 6, 11-15.	1.0	15
192	Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression. Annals of the Rheumatic Diseases, 2011, 70, 1292-1295.	0.5	71
193	Adiposity, joint and systemic inflammation: the additional risk of having a metabolic syndrome in rheumatoid arthritis. Swiss Medical Weekly, 2011, 141, w13211.	0.8	18
194	Interleukin-1Î² and Interleukin-6 in Arthritis Animal Models: Roles in the Early Phase of Transition from Acute to Chronic Inflammation and Relevance for Human Rheumatoid Arthritis. Molecular Medicine, 2010, 16, 552-557.	1.9	100
195	Diagnostic performance of anti-citrullinated peptide antibodies for the diagnosis of rheumatoid arthritis: the relevance of likelihood ratios. Clinical Chemistry and Laboratory Medicine, 2010, 48, 829-34.	1.4	16
196	Association of autoimmune diseases to allele 2 of the 3' immuno-globulines HS1.2 enhancer bearing an NF-&x03BA;B binding site.. Nature Precedings, 2009, , .	0.1	0
197	Residual minimal disease activity in rheumatoid arthritis: a simple definition through an in-depth statistical analysis of the major outcome. Rheumatology, 2009, 48, 1242-1246.	0.9	6
198	Allele *2 of the HS1,2A enhancer of the Ig regulatory region associates with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2009, 68, 416-419.	0.5	24

#	Article	IF	Citations
199	Synovial B cells of rheumatoid arthritis express ZAP-70 which increases the survival and correlates with the inflammatory and autoimmune phenotype. Clinical Immunology, 2009, 131, 98-108.	1.4	14
200	ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. Arthritis Research and Therapy, 2009, 11, R163.	1.6	29
201	B cell depletion and a T cell-targeted therapy allows to control the sudden onset of diabetes and lupus, without steroids. Acta Diabetologica, 2008, 45, 195-196.	1.2	1
202	Chapter 8 Gastrointestinal Involvement in Systemic Vasculitis. Handbook of Systemic Autoimmune Diseases, 2008, 8, 83-298.	0.1	0
203	Analysis of response to infliximab in ankylosing spondylitis according to the axial and/or peripheral involvement: autoantibodies and drop outs are more frequent in the peripheral subset. Annals of the Rheumatic Diseases, 2007, 66, 427-428.	0.5	2
204	Hepatocyte growth factor and transforming growth factor Î²1 ratio at baseline can predict early response to cyclophosphamide in systemic lupus erythematosus nephritis. Arthritis and Rheumatism, 2006, 54, 3633-3639.	6.7	20
205	IL-1BandIL-1RNgene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. Pharmacogenomics, 2006, 7, 683-695.	0.6	75
206	Mononuclear cell response to lipopolysaccharide in patients with rheumatoid arthritis: relationship with tristetraprolin expression. Journal of Rheumatology, 2005, 32, 998-1005.	1.0	15
207	B cell depletion may lead to normalization of anti-platelet,anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosus. Thrombosis and Haemostasis, 2004, 92, 1150-1153.	1.8	20
208	Autoantibodies and thrombophilia in RA: TNFÂ and TNFÂ blockers. Annals of the Rheumatic Diseases, 2004, 63, 613-615.	0.5	12
209	Thrombogenicity of TNFÎ± in rheumatoid arthritis defined through biological probes: TNFÎ± blockers. Autoimmunity Reviews, 2004, 3, 261-266.	2.5	30
210	Relationship between the tumor necrosis factor receptor II (TNF-RII) gene polymorphism and sTNF-RII plasma levels in healthy controls and in rheumatoid arthritis. Human Immunology, 2004, 65, 1420-1426.	1.2	18
211	B cell depletion may lead to normalization of anti-platelet, anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosus. Thrombosis and Haemostasis, 2004, 92, 1150-3.	1.8	6
212	Platelet GPIIb/IIIa (P1A1/2) polymorphism in SLE: clinical and laboratory association. Annals of the Rheumatic Diseases, 2003, 62, 781-782.	0.5	5
213	Preliminary Classification of Nonmalignant B Cell Proliferation in SjÃ¶gren's Syndrome: Perspectives on Pathobiology and Treatment Based on an Integrated Clinico-Pathologic and Molecular Study Approach. Blood Cells, Molecules, and Diseases, 2001, 27, 757-766.	0.6	35
214	CYCLOSPORINE A PHARMACOKINETICS IN RHEUMATOID ARTHRITIS PATIENTS AFTER 6 MONTHS OF METHOTREXATE THERAPY. Pharmacological Research, 1999, 40, 483-486.	3.1	5
215	High CD14+ peripheral monocytes expression of ALX/FPR2 and BLT1 in low disease activity and remission status in rheumatoid arthritis: a piltot study. Clinical and Experimental Rheumatology, 0, , .	0.4	2